← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksARWRPrice Target
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

Arrowhead Pharmaceuticals, Inc. (ARWR) Price Target Analysis

Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026

Current Price
$63.27
Market reference
Price Target
$78.78
+24.5% Upside
Target Range
$35.00 — $110.00
Very wide disagreement
Analyst Rating
Buy
20 analysts
Forward P/E—
Trailing P/E-5186.1x
Forward PEG—
Implied Growth-323.4%
Median Target$80.00
Analyst Spread95.2%

Analysts see +24.5% upside to their consensus target of $78.78. The bullish rating consensus aligns with positive price target gap.

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$63.27
Consensus$78.78
High$110.00
Low$35.00
Bear Case
$35
-44.7%
Consensus
$79
+24.5%
Bull Case
$110
+73.9%

Analyst Ratings Distribution

Breakdown of 20 published analyst recommendations for ARWR

14/20 analysts are bullish
+35
BearishBullish
Weighted analyst sentiment score based on 20 ratings
ConsensusBuy
Coverage20 Analysts
Net Score+35
Bull / Bear70% / 0%
Strong Buy00%
Buy1470%
Hold630%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
1470%
Hold
630%
Sell
00%
Strong Sell
00%
Recommendation Mix70% Buy · 30% Hold · 0% Sell
Buy (14)Hold (6)Sell (0)

ARWR Price Target Analysis

Updated February 28, 2026

As of February 28, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) has a Wall Street consensus price target of $78.78, based on estimates from 20 covering analysts. With the stock currently trading at $63.27, this represents a potential upside of +24.5%. The company has a market capitalization of $8.69B.

Analyst price targets range from a low of $35.00 to a high of $110.00, representing a 95% spread in expectations. The median target of $80.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.

The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, ARWR trades at a trailing P/E of -5186.1x. Analysts expect EPS to grow -323.4% over the next year.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside+80.1%
Avg Forward P/E49.0x
Peers with Coverage10 / 10
CompanyMarket CapPriceTargetUpsideRatingFwd P/EAnalysts
ARWRArrowhead Pharmaceuticals, Inc.
$8.7B$63.27$78.78+24.5%Buy—20
ALNYAlnylam Pharmaceuticals, Inc.$44.1B$332.92$461.06+38.5%Buy49.0x51
IONSIonis Pharmaceuticals, Inc.$13.3B$81.15$89.13+9.8%Buy—32
CRSPCRISPR Therapeutics AG$5.6B$60.14$65.00+8.1%Buy—38
BEAMBeam Therapeutics Inc.$2.9B$28.46$40.86+43.6%Buy—27
WVEWave Life Sciences Ltd.$2.2B$13.93$32.00+129.7%Buy—24
RNAAvidity Biosciences, Inc.$2.2B$14.75$74.67+406.2%Buy—20
STOKStoke Therapeutics, Inc.$2.0B$36.41$42.75+17.4%Buy—15
NTLAIntellia Therapeutics, Inc.$1.6B$13.78$19.38+40.6%Buy—38
ABUSArbutus Biopharma Corporation$895M$4.66$8.50+82.4%Buy—10

Upside Potential Comparison

RNA
+406.2%
WVE
+129.7%
ABUS
+82.4%
BEAM
+43.6%
NTLA
+40.6%
ALNY
+38.5%
ARWR
+24.5%
STOK
+17.4%

See ARWR's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is ARWR Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare ARWR vs AGIO

See how ARWR stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

What is the ARWR stock price target for 2026?

The consensus Wall Street price target for ARWR is $78.78, representing 24.5% upside from the current price of $63.27. With 20 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is ARWR a buy, sell, or hold?

ARWR has a consensus rating of "Buy" based on 20 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $78.78 implies 24.5% upside from current levels.

Is ARWR stock overvalued or undervalued?

ARWR's current price is $63.27 with a consensus target of $78.78 (24.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.

How high can ARWR stock go?

The most bullish Wall Street analyst has a price target of $110 for ARWR, while the most conservative target is $35. The consensus of $78.78 represents the median expectation. These targets typically reflect 12-month expectations.

How many analysts cover ARWR stock?

ARWR is well covered by analysts, with 20 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the ARWR stock forecast?

The 12-month ARWR stock forecast based on 20 Wall Street analysts shows a consensus price target of $78.78, with estimates ranging from $35 (bear case) to $110 (bull case). The median consensus rating is "Buy".

Should I buy ARWR stock?

Wall Street analysts are very optimistic on ARWR, with a "Buy" consensus rating and $78.78 price target (24.5% upside). 14 of 20 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do ARWR price targets vary so much?

ARWR analyst price targets range from $35 to $110, a 95% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $78.78 consensus represents the middle ground.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.